Entering to the U.S. market will be visualize as 10 companies are undergoing challenges to get FDA’s approvals
Korean pharmaceutical companies will hit stride in their global challenges targeting the U.S. market.
As the impotency drug that Mezzion, a new drug development company, made partnership with Actavis is expected to be approved by FDA next year, new drugs, such as a blood product of Green Cross, ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
